Cetuximab, an antibody which binds the extracellular domain of EGFR and blocks dimer formation [65], has therefore been explored as a potential treatment in combination with EGFR kinase inhibition in EGFR exon 20 insertion mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.